Roy H. Decker, MD, PhD, discusses the use of pembrolizumab with concurrent chemoradiotherapy in patients with inoperable, locally advanced non–small cell lung cancer.
Findings from a new study led by Yale Cancer Center researchers shows that the enzyme KDM5B suppresses anti-melanoma immunity, which could help develop a new treatment strategy to benefit patients with melanoma and other cancers.
In the past 2 years, key data from clinical trials in advanced lung cancer have demonstrated that immunotherapy has expanded the bounds of the armamentarium for the treatment of several lung cancers.
Ian E. Krop, MD, PhD, has been appointed chief clinical research officer, associate cancer center director for clinical research, and director of the Yale Cancer Center Clinical Trials Office.
New research led by Yale Cancer Center revealed White patients had significantly more telemedicine visits compared with Black patients for hematologic cancer care during the COVID-19 pandemic.
The combination of ixabepilone and bevacizumab significantly improved progression-free survival vs ixabepilone alone in the treatment of platinum-resistant ovarian cancer, according to data from the phase 2 trial published in the British Journal of Cancer.
The National Cancer Institute recently awarded Yale Cancer Center and Yale School of Public Health a new U01 cooperative agreement grant to support research into the impact of diet and exercise for women with ovarian cancer.
Aarti Bhatia, MD, discusses the rationale for investigating berzosertib in this patient population, key updates from the phase 1 trial, and how these findings support the need for continued research of novel regimens in HNSCC.
Barbara Burtness, MD, has been named Chief Translational Research Officer for Yale Cancer Center and Smilow Cancer Hospital and Associate Cancer Center Director for Translational Research for Yale Cancer Center.
An overview of first-line treatment options in SCLC with expert insights on important considerations in guiding treatment selection.
Panel experts discuss strategies aimed at preventing and managing potential adverse events with first-line combination therapy approaches in extensive stage small-cell lung cancer.
Faculty discuss potential treatment approaches for limited stage small-cell lung cancer currently under investigation in the ADRIATIC and other ongoing trials.
Expert oncologists present the case of a 45-year-old woman with synaptophysin-positive, extensive-stage small-cell lung cancer with a Ki-67 score of 90%, who is treated with carboplatin, etoposide, and atezolizumab in the first-line setting, and provide their initial impressions.
Faculty discuss real world data for treatment approaches using chemotherapy in combination with immunotherapy in extensive-stage small-cell lung cancer.
A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.
Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.
A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.
Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.